GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

GSA Capital Partners LLP raised its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 525.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 137,151 shares of the company's stock after purchasing an additional 115,223 shares during the quarter. GSA Capital Partners LLP owned 0.15% of Aquestive Therapeutics worth $683,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $27,000. nVerses Capital LLC purchased a new stake in Aquestive Therapeutics in the 3rd quarter worth approximately $28,000. SG Americas Securities LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $76,000. Finally, Financial Advocates Investment Management grew its holdings in Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company's stock valued at $88,000 after buying an additional 14,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners increased their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Aquestive Therapeutics currently has an average rating of "Buy" and a consensus target price of $9.80.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST traded up $0.20 during midday trading on Monday, reaching $4.64. 1,454,303 shares of the stock traded hands, compared to its average volume of 1,752,910. The stock has a market capitalization of $423.07 million, a PE ratio of -9.80 and a beta of 2.82. Aquestive Therapeutics, Inc. has a one year low of $1.73 and a one year high of $6.23. The company's 50 day moving average is $4.99 and its 200 day moving average is $3.88.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts' expectations of $12.69 million. During the same period in the prior year, the company earned ($0.03) EPS. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.